Product news from the 10/31/06 News Brief

Share this article:
The FDA has approved Novartis’ Tyzeka (telbivudine) for patients with chronic hepatitis B. Alpharma won FDA approval for its 80 mg dosage strength of chronic pain treatment Kadian (morphine sulfate). The company expects to launch this new dosage strength during the fourth-quarter of 2006. Kadian is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.